(WSJ) – Novel approaches go after 85% of disease drivers that researchers haven’t been able to attack

A new class of medications—known as “protein degraders”—are showing promise in going after a certain kind of hard-to-target protein in diseased cells. Most medicines on the market today work by latching onto the rough surface of a protein and blocking it from causing disease. But some proteins are so flat that they are hard to latch on to. These elusive, smooth proteins are involved in 85% of disease drivers that researchers have so far been unable to attack. (Read More)